REPL
Replimune Group, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
14.67
▲ 0.62 (4.40%)
MARKET · —
Price
Open
14.05
Prev close
14.05
Day high
14.98
Day low
13.81
Volume
2.94M
Market cap
$1.39B
P/E (TTM)
—
52W range
1.50 – 15.71
Trailing performance
Returnvs SPY
1W
-1.34%
+0.0%
1M
+41.20%
+37.5%
3M
+182.95%
+179.9%
6M
+70.95%
+59.9%
YTD
+51.95%
+39.7%
1Y
+181.33%
+161.3%
3Y
-21.44%
-95.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.39B
Enterprise value$1.31B
Revenue (TTM)—
Gross profit—
EBITDA$-290.44M
Net income$-297.01M
EPS (TTM)$-3.15
Free cash flow$-171.67M
Total cash$195.33M
Total debt$111.97M
Book value / share$1.26
Shares outstanding94.22M
Float67.61M
Short % of float57.95%
Dividend yield—
Beta (5Y)0.90
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.03
PEG ratio—
Price / sales—
Price / book11.74
EV / revenue—
EV / EBITDA-4.50
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-134.29%
Return on assets-51.30%
Debt / equity105.99
Current ratio5.23
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$313.94M | -$247.30M | -$215.79M | -$174.28M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net income | -$313.94M | -$247.30M | -$215.79M | -$174.28M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.77 | -0.72 | +6.3% |
| Mar 2026 | -0.72 | -0.76 | -5.6% |
| Dec 2025 | -0.82 | -0.77 | +6.5% |
| Sep 2025 | -0.79 | -0.90 | -13.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.75 | 5 | $0 | 0.0% |
| Next quarter | -0.70 | 5 | $6.80M | 0.0% |
| Current year | -2.78 | 4 | $42.73M | 0.0% |
| Next year | -1.37 | 3 | $181.84M | +325.6% |
Analyst targets & ownership
Mean target$19.33
High target$24.00
Low target$14.00
Implied upside31.80%
Analyst count6
ConsensusBUY
Strong buy / Buy2 / 5
Hold0
Sell / Strong sell1 / 0
Held by insiders1.70%
Held by institutions104.19%
Institutions holding252
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+321.95K
Net buying
Buy transactions
7
512.91K shares
Sell transactions
13
190.96K shares
Net transactions
+20
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
1.60M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | HILL EMILY LUISA Chief Financial Officer |
SELL | 9.26K | $132.18K | Direct |
| Aug 10, 26 | HILL EMILY LUISA Chief Financial Officer |
SELL | 11.45K | $148.48K | Direct |
| Aug 10, 26 | PATEL SUSHIL Chief Executive Officer |
SELL | 39.34K | $510.25K | Direct |
| Aug 10, 26 | XYNOS KONSTANTINOS Officer |
SELL | 11.45K | $148.47K | Direct |
| Aug 10, 26 | SCHWENDENMAN ANDREW Officer |
SELL | 7.63K | $98.99K | Direct |
| Jun 1, 26 | SARCHI CHRISTOPHER Officer |
SELL | 12.00K | $110.88K | Direct |
| May 18, 26 | HILL EMILY LUISA Chief Financial Officer |
SELL | 7.81K | $39.69K | Direct |
| May 18, 26 | PATEL SUSHIL Chief Executive Officer |
SELL | 37.32K | $189.61K | Direct |
| May 18, 26 | XYNOS KONSTANTINOS Officer |
SELL | 14.02K | $71.24K | Direct |
| May 18, 26 | SCHWENDENMAN ANDREW Officer |
SELL | 7.89K | $40.10K | Direct |
| May 18, 26 | SARCHI CHRISTOPHER Officer |
SELL | 8.63K | $43.82K | Direct |
| May 18, 26 | ASTLEY-SPARKE PHILIP Director |
SELL | 17.66K | $89.70K | Direct |
| Apr 2, 26 | SARCHI CHRISTOPHER Officer |
SELL | 6.50K | $52.06K | Direct |
| Apr 1, 26 | ASTLEY-SPARKE PHILIP Director |
STOCK | 50.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ASTLEY-SPARKE PHILIP |
Director | 1.41M | Sale |
DHINGRA KAPIL |
Director | 0 | Sale |
HILL EMILY LUISA |
Chief Financial Officer | 215.85K | Sale |
PATEL SUSHIL |
Chief Executive Officer | 708.15K | Sale |
SARCHI CHRISTOPHER |
Officer | 180.96K | Sale |
SCHWENDENMAN ANDREW |
Officer | 99.42K | Sale |
XYNOS KONSTANTINOS |
Officer | 224.22K | Sale |
Moving averages & technicals
SMA 10
14.66
+0.09% from price
SMA 20
12.16
+21.49% from price
SMA 50
11.16
+32.32% from price
SMA 100
8.11
+80.93% from price
SMA 200
8.26
+78.80% from price
EMA 12
13.95
+5.16% from price
EMA 26
12.59
+16.50% from price
EMA 50
11.17
+31.34% from price
RSI (14)
61.6
Neutral
MACD (12,26,9)
1.36
Hist 0.15
ATR (14)
1.36
9.19% of price
Realised vol 30D
267.2%
Annualised
Bollinger upper
18.76
20, 2σ
Bollinger lower
5.56
20, 2σ
50 / 200 cross
Golden
11.16 vs 8.26
Trend bias
Above 200
+78.80%
Risk profile
Beta vs SPY
1.25
More volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
267.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-84.2%
Peak to trough
Max drawdown 5Y
-95.0%
Peak to trough
ATR 14
1.36
9.19% of price
Beta (reported)
0.90
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.46
Put-heavy session
Put / call open interest
4.70
Positioning, not flow
Max pain
14.00
-5.2% from spot
ATM implied vol
83.2%
Nearest strike to spot
Skew (10% OTM)
-14.8%
Calls bid over puts
Call volume
208
Contracts, this expiry
Put volume
304
Contracts, this expiry
Heaviest call OI
22.00
490 contracts
Heaviest put OI
0.50
3.38K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 3d ago
Replimune Fiscal Q1 Net Loss Narrows
MT Newswires · 8d ago
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
GlobeNewswire · 8d ago
Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment
Simply Wall St. · 9d ago
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase
NewMediaWire · 11d ago
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
Stocktwits · 11d ago
REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’
Stocktwits · 12d ago
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News.
Barrons.com · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.